CLINICAL_TRIALS
trial_result
· 2013-08-02
Clinical Trial Update: Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome [Phase 3]
Summary
Phase 3 trial results update evaluating growth hormone for neuroendocrine dysfunction in patients with severe fibromyalgia syndrome.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Fibromyalgia | Phase 3 | Status: COMPLETED | Results posted: 2013-08-02